The Food and Drug Administration (FDA) has postponed its decision whether to approve an antidote to the blood thinners Xarelto and Eliquis, pushing the action date from early February to early May in order to consider additional information it had requested from the manufacturer. The news came as a blow not only to Portola Pharmaceuticals, maker of the antidote called AndexXa, but also to Eliquis’ Pfizer and Bristol-Myers Squibb, and Xarelto’s Johnson & Johnson and Bayer. “The agency has instituted an extension to allow more time for a thorough review of the information provided and to work with the company ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.